EFFECTOR Therapeutics shares are trading higher after the company reported data updates from the Phase 2 expansion cohorts evaluating zotatifin in patients with ER+ metastatic breast cancer at the ASCO 2023 Annual Meeting.
Portfolio Pulse from Benzinga Newsdesk
EFFECTOR Therapeutics reported positive data updates from the Phase 2 expansion cohorts evaluating zotatifin in patients with ER+ metastatic breast cancer at the ASCO 2023 Annual Meeting, leading to higher trading of its shares.
May 26, 2023 | 12:44 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
EFFECTOR Therapeutics shares are trading higher after positive data updates from the Phase 2 expansion cohorts evaluating zotatifin in ER+ metastatic breast cancer patients.
The positive data updates from the Phase 2 expansion cohorts evaluating zotatifin in ER+ metastatic breast cancer patients indicate progress in the development of the drug. This news is likely to boost investor confidence in the company's potential, leading to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100